



Figure 3. Responder rates for (a) EVE and (b) CBD from the pivotal RCTs and OLE studies for TSC-associated epilepsy. There are no head-to-head trials of EVE versus CBD, nor any published indirect comparisons. Therefore, any comparisons of the efficacy of the two treatments should be made with caution due to differences in baseline patient demographics and clinical characteristics in the trial populations, and a difference in the placebo effect. CBD, cannabidiol; CBD25, CBD 25mg/kg/day; CBD50, CBD 50mg/kg/day;